Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)

Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)

Desde: GRACEcast
0 0 hace 7 años
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Síguenos en Facebook